← Back to guidelines
Cardiology1 paper

Carcinoma in situ of upper respiratory tract

Last edited: 5 h ago

Overview

Carcinoma in situ of the upper respiratory tract refers to non-invasive malignant epithelial neoplasms confined to the mucosal layer without local invasion. This condition is particularly rare in pediatric populations, where specific chromosomal aberrations like t(15;19) may indicate a distinct and aggressive clinical entity 1.

Diagnosis

  • Cytogenetic Analysis: Identification of chromosomal translocation t(15;19) can be diagnostic, especially in young patients 1.
  • Histopathology: Poorly differentiated carcinoma with vesicular nuclei, prominent nucleoli, and extensive necrosis; positive for cytokeratin markers 1.
  • Imaging: CT or MRI to assess tumor extent and involvement of adjacent structures 1.
  • Clinical Presentation: Rapidly growing masses, often in the epiglottis or nasopharynx, with potential for superior vena cava syndrome 1.
  • Management

  • Surgical Resection: Primary treatment for localized disease, aiming for complete removal 1.
  • Radiation Therapy: Adjunctive treatment, particularly for aggressive cases with high risk of recurrence 1.
  • Chemotherapy: Limited evidence in pediatric cases; specific drug classes and doses not detailed in current abstracts 1.
  • Special Populations

  • Pediatrics: Presence of t(15;19) suggests a distinct aggressive subtype with poor prognosis; management requires multidisciplinary approach 1.
  • Key Recommendations

  • Perform cytogenetic analysis, specifically looking for t(15;19) translocation, in pediatric patients with upper respiratory tract carcinoma for prognostic and diagnostic clarity (Evidence: Expert opinion) 1.
  • Consider aggressive surgical resection followed by adjuvant radiation therapy for localized carcinoma in situ, especially in pediatric cases with aggressive features (Evidence: Moderate) 1.
  • Closely monitor pediatric patients with carcinoma in situ due to the rapid progression and high mortality risk associated with t(15;19) translocation (Evidence: Weak) 1.
  • References

    1 Vargas SO, French CA, Faul PN, Fletcher JA, Davis IJ, Dal Cin P et al.. Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer 2001. link92:5<1195::aid-cncr1438>3.0.co;2-3)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Pricing·Privacy & Terms·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG